Collect Product
Product Details
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
Description
The STAT3 (Luc) HEK293 Reporter Cell was engineered with the STAT3 response element driving luciferase expressing systems. The receptors expressing endogenously or transfected on this reporter cell were activated by corresponding ligands binding, transducing intracellular signals resulting in STAT3-RE mediated luminescence.
Application
• The discovery of activators or inhibitors by the STAT3 signaling bioactivity.
• Transfection host for some receptors concerning the STAT3 signaling pathway.
Growth Properties
Adherent
Selection Marker
Hygromycin B (40 μg/mL)
Complete Growth Medium
DMEM medium + 10% FBS
Freeze Medium
Serum-free cell cryopreservation medium
Quantity
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
Storage
Frozen in liquid nitrogen.
Mycoplasma Testing
Negative
Sterility Testing
Negative
Instructions for Use
See data sheet for detailed culturing and assay protocol.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
Application
Inhibition of human IL-6 protein-induced reporter activity by anti-human IL-6 neutralizing antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of human IL-6 protein (Cat. No. IL6-H4218) with a final concentration of 2.5 ng/mL. The EC50 of anti-human IL-6 neutralizing antibody is approximately 0.04 μg/mL.Protocol
Inhibition of human IL-6 protein-induced reporter activity by JAK inhibitor.
This reporter cell was incubated with serial dilutions of JAK inhibitors in the presence of human IL-6 protein (Cat. No. IL6-H4218) with a final concentration of 2.5 ng/mL. The EC50 of JAK inhibitor (Baricitinib) was approximately 0.0108 μM.
Protocol
Signaling Bioassay
Response to human IL-6 protein (RLU).
The STAT3 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-6 protein (Cat. No. IL6-H4218). The EC50 was approximately 2.2 ng/mL.Protocol
Response to human IL-6 protein (FOLD).
The STAT3 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-6 protein (Cat. No. IL6-H4218). The max induction fold was approximately 100.5.Protocol
Passage Stability
Passage stability analysis by Signaling Bioassay.
The continuously growing STAT3 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-6 protein (Cat. No. IL6-H4218). Human IL-6 protein stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 9-37.Protocol
User Reviews Publish Comment
Important Statement
Limited Use&License Disclosure
BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.
- If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
- Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
- This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use. You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
- ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
- ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
- Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.
Frontier Progress
Drug Development Progress- English Name：
Signal transducer and activator of transcription 3
- Category：
- Listed Drugs Count：
4 Details
- Clinical Drugs Count：
21 Details
- Highest R&D Stage：
Approved
Contact Us
Drug Candidate Licensing
